SIM
SCPH

Spark Investment Management’s scPharmaceuticals SCPH Stock Holding History

Spark Investment Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,720
Closed -$60K – 726
2018
Q2 		$60K Buy
+10,720
New +$110K ﹤0.01% 632

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spark Investment Management's SCPH Position: Q3 2018 in Review

Spark Investment Management sold out of scPharmaceuticals (SCPH) in Q3 2018, closing a stake of 10,720 shares — an estimated $60K sold.

Spark Investment Management first reported a position in SCPH in Q2 2018 and held it in 1 quarter. The position peaked at $60K in Q2 2018. 35 funds tracked by Wall St. Rank hold SCPH as of Q3 2018.

  • Spark Investment Management reported no remaining scPharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Spark Investment Management sold 10,720 scPharmaceuticals shares in Q3 2018, an estimated $60K.
  • Spark Investment Management first reported a position in scPharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Spark Investment Management's scPharmaceuticals position peaked at $60K in Q2 2018.
  • 35 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2018.

Based on Spark Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.